However, temporal associations in this case were complicated by several factors
Germany leads with 17.0% in 2025, rising to 18.0% by 2035, supported by strong medical-wellness adoption across Berlin, Munich, Frankfurt, and Hamburg
Related topics Topic Replies Views Activity New weight loss drugs....a overview MBBS 2 23 July 8, 2026 Drug of the Week: Science Behind Weight Loss Drug (SEMAGLUTIDE) General 10 66 May 11, 2026 Semaglutide: A Breakthrough GLP-1 Receptor Agonist in Diabetes and Obesity Management Pharmacy mbbs , medical , futuredoctors 3 50 October 27, 2025 Semaglutide : Drug Profile Pharmacy 3 39 June 30, 2026 Updates In Diabetes Management : GLP-1 Agonists VS SGLT-2 Inhibitors Pharmacy 0 21 March 7, 2026 Home Categories Guidelines Terms of Service Privacy Policy Powered by Discourse, best viewed with JavaScript enabled
When to seek medical attention Most injection-related issues are minor and self-resolving
In clinical trials of tirzepatide, they seemed to be slightly more common with higher doses of the drug